HK Stock Market Move | In the morning session, Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 7%, and its application for the listing permit of Rivaroxaban tablets was accepted by the European Medicines Agency (EMA).

Jiangsu Hengrui Pharmaceuticals (01276) rose nearly 7% in early trading, up 4.64% as of the time of writing, at HK$57.5, with a trading volume of HK$1.46 billion. On the news front, Jiangsu Hengrui Pharmaceuticals announced that its independently developed innovative drug, Rivuramine tablets, have received official acceptance of the application for market approval by the European Medicines Agency (EMA). This is Hengrui's first innovative drug submitted for market approval to the EU as an independent original research entity, marking a new stage in the company's internationalization strategy, transitioning from the early licensing-out model to independently targeting the mainstream European and American markets with core innovative drugs. Public information shows that after being included in the national medical insurance catalog in 2024, the accessibility of Rivuramine for patients will significantly increase, the coverage of hospitals will continue to expand, and sales growth will continue to outpace the industry average. By 2025, its domestic sales reached 1.851 billion yuan, ranking among the top tier of domestic innovative drugs for urological tumors. According to Evaluate Pharma data, the global sales of second-generation androgen receptor inhibitors are expected to reach a total of $12.89 billion in 2025.